Long-term daclizumab therapy in relapsing-remitting multiple sclerosis | Zendy

Monica A Rojas | Zendy; Noel G. Carlson | Zendy; Thomas L. Miller | Zendy; John Rose | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

Author(s) -

Monica A Rojas,

Noel G. Carlson,

Thomas L. Miller,

John Rose

Publication year - 2009

Publication title -

therapeutic advances in neurological disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.684

H-Index - 50

eISSN - 1756-2864

pISSN - 1756-2856

DOI - 10.1177/1756285609337992

Subject(s) - medicine , daclizumab , multiple sclerosis , relapsing remitting , term (time) , natalizumab , ocrelizumab , dimethyl fumarate , intensive care medicine , dermatology , immunology , rituximab , tacrolimus , lymphoma , transplantation , physics , quantum mechanics

We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant reduction in relapse rate and improvement in Expanded Disability Status Scores (EDSSs) (p < 0.0001). Long-term treatment with daclizumab in RR MS patients has apparent benefit that will require formal confirmation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research